Cigarette-Smoking Intensity and Interferon-Gamma Release Assay Conversion among Persons Who Inject Drugs: A Cohort Study
- PMID: 23304497
- PMCID: PMC3529865
- DOI: 10.1155/2012/828106
Cigarette-Smoking Intensity and Interferon-Gamma Release Assay Conversion among Persons Who Inject Drugs: A Cohort Study
Abstract
We analyzed data from a longitudinal cohort study of persons who inject drugs (PWID) in Tijuana, Mexico, to explore whether cigarette smoking increases the risk of interferon gamma release assay (IGRA) conversion. PWID were recruited using respondent driven sampling (RDS). QuantiFERON-TB Gold In-Tube (QFT) assay conversion was defined as interferon-gamma concentrations <0.35 IU/mL at baseline and ≥0.7 IU/mL at 18 months. We used multivariable Poisson regression adjusted for RDS weights to estimate risk ratios (RRs). Of 129 eligible participants, 125 (96.9%) smoked at least one cigarette during followup with a median of 11 cigarettes smoked daily, and 52 (40.3%) had QFT conversion. In bivariate analysis, QFT conversion was not associated with the number of cigarettes smoked daily (P = 0.716). Controlling for age, gender, education, and alcohol use, the RRs of QFT conversion for smoking 6-10, 11-15, and ≥16 cigarettes daily compared to smoking 0-5 cigarettes daily were 0.9 (95% confidence interval (CI), 0.5-1.6), 0.5 (95% CI, 0.3-1.2), and 0.7 (95% CI, 0.3-1.6), respectively. Although this study did not find an association between self-reported smoking intensity and QFT conversion, it was not powered sufficiently to negate such an association. Larger longitudinal studies are needed to fully explore this relationship.
Figures


Similar articles
-
Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study.Lancet Respir Med. 2017 Apr;5(4):282-290. doi: 10.1016/S2213-2600(17)30060-7. Epub 2017 Feb 16. Lancet Respir Med. 2017. PMID: 28215501 Free PMC article.
-
Negative effect of smoking on the performance of the QuantiFERON TB gold in tube test.BMC Infect Dis. 2012 Dec 27;12:379. doi: 10.1186/1471-2334-12-379. BMC Infect Dis. 2012. PMID: 23270417 Free PMC article.
-
Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube Interferon Gamma Release Assays in Patients at Risk for Tuberculosis and in Health Care Workers.J Clin Microbiol. 2018 Jun 25;56(7):e00614-18. doi: 10.1128/JCM.00614-18. Print 2018 Jul. J Clin Microbiol. 2018. PMID: 29743310 Free PMC article.
-
Relevance of QuantiFERON-TB Gold Plus and Heparin-Binding Hemagglutinin Interferon-γ Release Assays for Monitoring of Pulmonary Tuberculosis Clearance: A Multicentered Study.Front Immunol. 2021 Feb 2;11:616450. doi: 10.3389/fimmu.2020.616450. eCollection 2020. Front Immunol. 2021. PMID: 33603746 Free PMC article.
-
[Evolution of IGRA researches].Kekkaku. 2008 Sep;83(9):641-52. Kekkaku. 2008. PMID: 18979999 Review. Japanese.
Cited by
-
Smoking associates with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus.Lupus Sci Med. 2021 Oct;8(1):e000537. doi: 10.1136/lupus-2021-000537. Lupus Sci Med. 2021. PMID: 34725185 Free PMC article.
-
Dose-response association between salivary cotinine levels and Mycobacterium tuberculosis infection.Int J Tuberc Lung Dis. 2013 Nov;17(11):1452-8. doi: 10.5588/ijtld.13.0311. Int J Tuberc Lung Dis. 2013. PMID: 24125450 Free PMC article.
References
-
- WHO & The Union. Monograph on TB and Tobacco Control: Joining Efforts to Control Two Related Global Epidemics. Geneva, Switzerland: World Health Organization & International Union Against Tuberculosis and Lung Disease; 2007.
-
- Slama K, Chiang CY, Enarson DA, et al. Tobacco and tuberculosis: a qualitative systematic review and meta-analysis. International Journal of Tuberculosis and Lung Disease. 2007;11(10):1049–1061. - PubMed
-
- Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. Archives of Internal Medicine. 2007;167(4):335–342. - PubMed